LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) announced that its abstract on inhaled Molgramostim for Autoimmune Pulmonary Alveolar Proteinosis (aPAP) has been accepted for a poster presentation at the 2024 European Respiratory Society (ERS) Congress. The event will be held from September 7-11, 2024, in Vienna, Austria.
The abstract, titled “Inhaled Molgramostim Improves Pulmonary Gas Exchange and Respiratory Health-Related Quality of Life (HRQoL) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP): Results from IMPALA-2,” will be presented in Poster Session PS-29 on September 8 from 12:30-14:00 CET. This presentation underscores significant advancements in the treatment of aPAP, offering new hope for patients afflicted by this rare lung disease.
In addition to the poster presentation, Savara Inc. is sponsoring an Industry Symposium titled “Pulmonary Alveolar Proteinosis: Pathophysiology, Diagnosis, and Management.” The symposium will take place on September 8 from 17:30-19:00 CET at the ERS Congress Industry Theater. Esteemed speakers including Dr. Cormac McCarthy, Dr. Elisabeth Bendstrup, and Dr. Francesco Bonella will lead the session, providing insights into the complexities and management of the condition.
Savara’s participation in the ERS Congress aims to highlight advanced research and treatment options for aPAP, reinforcing its role in the global healthcare community.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.